← All Olema Pharmaceuticals, INC filings

Olema Pharmaceuticals, INC 8-K filings

NASDAQ
OLMA
Olema Pharmaceuticals, INC
8-K: Olema Oncology Reports Full-Year 2023 Financial Results and Provides Corporate Update
Olema Pharmaceuticals reported its 2023 financial results, highlighted clinical progress with palazestrant, and announced a new development candidate for their KAT6 program.